Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2013
Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation.Frontiers in pharmacology · 2024Article
- α-Gal Nanoparticles Mediated Homing of Endogenous Stem Cells for Repair and Regeneration of External and Internal Injuries by Localized Complement Activation and Macrophage Recruitment.International journal of molecular sciences · 2022Review
- Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement.Stem cells translational medicine · 2022Review
- R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling.Blood advances · 2021Article
- An irradiated marrow niche reveals a small noncollagenous protein mediator of homing, dermatopontin.Blood advances · 2021Article
- Umbilical cord blood: The promise and the uncertainty.Stem cells translational medicine · 2020Review
- Mechanistic Basis of ex Vivo Umbilical Cord Blood Stem Progenitor Cell Expansion.Stem cell reviews and reports · 2020Review
- Clinical Advancement and Challenges ofClinical hematology international · 2020Review
- Cord blood research, banking, and transplantation: achievements, challenges, and perspectives.Bone marrow transplantation · 2020Review
- Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies.F1000Research · 2020Review
- Umbilical Cord Blood Transplants: Current Status and Evolving Therapies.Frontiers in pediatrics · 2020Review
- Optimizing cord blood selection.Hematology. American Society of Hematology. Education Program · 2019Review
- Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells.International journal of hematology · 2019Review
- Cord blood transplantation for bone marrow failure syndromes: state of art.Stem cell investigation · 2019Review
- Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation.Current hematologic malignancy reports · 2016Article
- Emerging Strategies to Enhance Homing and Engraftment of Hematopoietic Stem Cells.Stem cell reviews and reports · 2016Review
- How to Improve Cord Blood Engraftment?Frontiers in medicine · 2016Review
- A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.Bone marrow transplantation · 2015Article
- Membrane lipid rafts, master regulators of hematopoietic stem cell retention in bone marrow and their trafficking.Leukemia · 2015Review
- Advances in umbilical cord blood manipulation-from niche to bedside.Nature reviews. Clinical oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Preclinical data showed that priming CD34(+) hematopoietic progenitor cells with complement fragment 3a (C3a) improved homing and engraftment. Thus, we hypothesized that priming of umbilical cord blood (UCB) hematopoietic progenitors with C3a would facilitate homing and could potentially be used to address the need for improved engraftment after UCB transplantation. We primed 1 of 2 UCB units for double UCB transplantation after nonmyeloablative conditioning. This design provided adequate safety and the potential to observe skewed long-term chimerism in favor of the C3a-primed unit as a surrogate measure of efficacy. C3a priming of 1 UCB unit did not result in infusional toxicity. Increased grades 1 to 3 hypertension were the only infusional adverse events observed in 9 (30%) patients. We observed no activation of inflammatory or coagulation pathways downstream of C3a. As tested, C3a priming did not impair engraftment, but did not skew chimerism toward the treated unit. As compared with historical controls, mortality and survival were not adversely affected. Thus, before any additional clinical studies, C3a priming to promote engraftment will require further preclinical optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.